D-0504-2023 Class II Terminated
FDA drug recall D-0504-2023 was initiated by Preferred Pharmaceuticals, Inc. on Mar 27, 2023 and is designated Class II. Reason for recall: CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination. The recall status is terminated (terminated Oct 24, 2023). Affected quantity: 30 Bottles.
Recall Details
- Product Type
- Drugs
- Report Date
- Apr 12, 2023
- Initiation Date
- Mar 27, 2023
- Termination Date
- Oct 24, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 30 Bottles
Product Description
Alprazolam Tab, USP 0.25mg, (CIV), 30-count bottle, Rx Only, Preferred Pharmaceuticals, Inc. Manufactured by: Breckenridge Pharmaceuticals, Inc., Boca Raton, FL. Ins:NDC 68788-7594-3
Reason for Recall
CGMP Deviations: Downstream recall from Breckenridge Pharmaceuticals, Inc due to potential risk of Cross Contamination.
Distribution Pattern
Nationwide in the USA
Code Information
Lot: G1822K, Exp. Date:5/31/2023.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0504-2023
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026